Constitutive and conditional mutant mouse models for understanding dopaminergic regulation of orofacial movements: Emerging insights and challenges

Journal of Pharmacological Sciences

Volumn 119, Issue 4, 2012, Pages 297-301

  Tomiyama, Katsunori ^a   Drago, John ^b   Waddington, John L ^c   Koshikawa, Noriaki ^a  

^a NIHON UNIVERSITY   (Japan)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Conditional mutant; Constitutive knockout; Orofacial movement

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR;

CONDITIONAL MUTATION; CONSTITUTIVE KNOCKOUT; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; EXPERIMENTAL MODEL; FOREBRAIN; GENE MUTATION; GENE SILENCING; HEAD MOVEMENT; INCISOR; JAW MOVEMENT; MASTICATION; MOUSE MUTANT; MOVEMENT (PHYSIOLOGY); NONHUMAN; OROFACIAL MOVEMENT; PROMINENT TONGUE; REGULATORY MECHANISM; REVIEW; VIBRISSA;

EID: 84865404269     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.12R05CP     Document Type: Review

References (27)

1. Cardoso F, Seppi K, Mair KJ, Wenning GK, Poewe W. Seminar on choreas. Lancet Neurol. 2006;5:589-602.
2. Walker FO. Huntington's disease. Lancet. 2007;369:218-228.
3. Friedlander AH, Mahler M, Norman KM, Ettinger RL. Parkinson disease: systemic and orofacial manifestations, medical and dental management. J Am Dent Assoc. 2009;140:658-669.
4. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet. 2009;373:2055-2066.
5. Estep ME. Modulation, adaptation, and control of orofacial pathways in healthy adults. J Commun Disord. 2009;42:280-285.
6. Gossard JP, Dubuc R, Kolta A, editors. Breathe, walk and chew: the neural challenge: Part I. In: Progress in brain research, Vol. 187. Amsterdam: Elsevier B.V.; 2011. p. 2-230.
7. Gossard JP, Dubuc R, Kolta A, editors. Breathe, walk and chew: the neural challenge: Part II. In: Progress in brain research, Vol. 188. Amsterdam: Elsevier B.V.; 2011. p. 2-252.
8. Kobayashi M, Koshikawa N, Iwata K, Waddington J, editors. Translating mechanisms of orofacial neurological disorder. In: International review of neurobiology, Vol. 97. San Diego: Academic Press; 2011. p. 1-381.
9. Waddington JL, Daly SA, Downes RP, Deveney AM, McCauley PG, O'Boyle KM. Behavioural pharmacology of 'D1-like' dopamine receptors: further subtyping, new pharmacological probes and interactions with 'D2-like' receptors. Prog Neuro-Psychopharmacol Biol Psychiatry. 1995;19:811-831.
10. Koshikawa N, Fujita S, Adachi K. Behavioral pharmacology of orofacial movement disorders. Int Rev Neurobiol. 2011;97:1-38.
11. Tomiyama K, O'Tuathaigh C, Waddington JL. Regulation of orofacial movement: amino acid mechanisms and mutant models. Int Rev Neurobiol. 2011;97:61-75.
12. Missale C, Fiorentini C, Collo G, Spano P. The neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexes. J Recept Signal Transduct Res. 2010;30:347-354.
13. Waddington JL, O'Tuathaigh C, O'Sullivan G, Tomiyama K, Koshikawa N, Croke DT. Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface. Psychopharmacology. 2005;181:611-638.
14. O'Sullivan GJ, O'Tuathaigh C, Tomiyama K, Koshikawa N, Waddington JL. Dopamine receptor subtypes and behaviour: from psychopharmacology to mutant models. In: Neve KA, editor. The dopamine receptors. Totowa, NJ: Humana Press; 2010. p. 323-371.
15. Kalueff AV, Bergner CL, editors. Transgenic and mutant tools to model brain disorders. New York: Springer; 2010.
16. 2-like receptor regulation. Eur J Pharmacol. 2001;418:47-54.
17. Tomiyama K, Waddington JL, Koshikawa N. [Observation and recording of mouse jaw movements with a novel restrictor system and a behavioral check list]. Nihon Yakurigaku Zasshi (Folia Pharmacol Jpn). 2006;128:244-249. (in Japanese)
18. Waddington JL, O'Sullivan GJ, Tomiyama K. Regulation of orofacial movement: dopamine receptor mechanisms and mutant models. Int Rev Neurobiol. 2011;97:39-60.
19. Waddington JL. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology. 1990;101:431-447.
20. 1A receptor "knockout" mice. Neuropharmacology. 2002;42:644-652.
21. 4 receptor or DARPP-32 transduction "knockout". Eur Neuropsychopharmacol. 2006;16:437-445.
22. Tomiyama K, McNamara FN, Clifford JJ, Kinsella A, Drago J, Fuchs S, et al. Comparative phenotypic resolution of spontaneous, D2-like and D1-like agonist-induced orofacial movement topographies in congenic mutants with dopamine D2 vs. D3 receptor "knockout". Synapse. 2004;51:71-81.
23. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 1990;13:266-271.
24. 2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci. 2007;30:228-235.
25. Tomiyama K, Kim HA, Kinsella A, Ehrlich ME, Schütz G, Koshikawa N, et al. Phenotypic disruption to orofacial movement topography in conditional mutants with generalized CamKIIa/Cre D1Tox versus striatal-specific DARPP-32/Cre D1Tox ablation of D1 dopamine receptor-expressing cells. Synapse. 2011;65:835-842.
26. Kim HA, Jiang L, O'Tuathaigh C, Waddington JL, Ehrlich ME, Lawrence AJ, et al. Selective ablation of D1 receptor-expressing neurons in the striatum is associated with Parkinsonism but not dystonia. J Neurochem. 2009;110 Suppl 2:259.
27. 1 dopamine receptor-expressing cells generates mice with seizures, dystonia, hyperactivity, and impaired oral behavior. Proc Natl Acad Sci U S A. 2007;104:4182-4187.